<code id='87784AB634'></code><style id='87784AB634'></style>
    • <acronym id='87784AB634'></acronym>
      <center id='87784AB634'><center id='87784AB634'><tfoot id='87784AB634'></tfoot></center><abbr id='87784AB634'><dir id='87784AB634'><tfoot id='87784AB634'></tfoot><noframes id='87784AB634'>

    • <optgroup id='87784AB634'><strike id='87784AB634'><sup id='87784AB634'></sup></strike><code id='87784AB634'></code></optgroup>
        1. <b id='87784AB634'><label id='87784AB634'><select id='87784AB634'><dt id='87784AB634'><span id='87784AB634'></span></dt></select></label></b><u id='87784AB634'></u>
          <i id='87784AB634'><strike id='87784AB634'><tt id='87784AB634'><pre id='87784AB634'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:9318
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          In key trial, Verve's treatment lowers cholesterol levels in patients

          APStockVerveTherapeuticssaidSundaythatthefirst10peopletoreceiveaone-timetreatmentpoweredbyaformofCRI